Dynavax Technologies (DVAX) 주식

Dynavax Technologies Corporation (DVAX) is a commercial-stage biotechnology company centred on vaccine adjuvant technology and vaccine development. Its core asset is CpG 1018, an adjuvant designed to enhance immune responses and used in approved vaccine formulations; the company also advances candidate vaccines and immuno-oncology approaches through internal programmes and partnerships. With a market capitalisation of around $1.19 billion, Dynavax generates revenues through product sales, licences and collaborations, but its financial profile can be uneven as clinical progress and partner deals evolve. Investors should note the typical biotech risks: clinical trial outcomes and regulatory decisions can be binary, competition is strong, and further capital raising may be required to fund development. This summary provides general educational information only and is not investment advice; suitability depends on individual circumstances and you should consult a professional before acting.